Phillip G. Billington - 26 Oct 2022 Form 4 Insider Report for HCA Healthcare, Inc. (HCA)

Role
SVP-Internal Audit Services
Signature
/s/ Kevin A. Ball, Attorney-in-Fact
Issuer symbol
HCA
Transactions as of
26 Oct 2022
Net transactions value
-$3,030,947
Form type
4
Filing time
28 Oct 2022, 18:07:10 UTC
Previous filing
23 Feb 2022
Next filing
01 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HCA Common Stock Options Exercise $616,258 +16,575 +41% $37.18* 57,227 26 Oct 2022 Direct F1
transaction HCA Common Stock Tax liability $1,792,688 -8,243 -14% $217.48 48,984 26 Oct 2022 Direct F1
transaction HCA Common Stock Sale $1,854,518 -8,332 -17% $222.58 40,652 28 Oct 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HCA Stock Appreciation Right Options Exercise $0 -8,500 -100% $0.000000* 0 26 Oct 2022 Common Stock 8,500 $37.18 Direct F3
transaction HCA Stock Appreciation Right Options Exercise $0 -8,075 -100% $0.000000* 0 26 Oct 2022 Common Stock 8,075 $37.18 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 2,176.1056 shares acquired under the HCA Holdings, Inc. Employee Stock Purchase Plan.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $222.50 to $222.77, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The stock appreciation rights vested in four equal annual installments beginning on February 6, 2014.
F4 The stock appreciation rights vested at the end of fiscal years 2013, 2014, 2015 and 2016 based upon the achievement of certain annual EBITDA performance targets.